Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker
Status:
Terminated
Trial end date:
2019-09-30
Target enrollment:
Participant gender:
Summary
Studies have shown that the study drug, pembrolizumab, works by helping the immune system. In
this way, pembrolizumab may help to slow the growth of melanoma or may cause cancer cells to
die. Compared to standard treatments, pembrolizumab seems to lengthen the time patients lived
overall and the time without their cancer getting worse.